SciELO - Scientific Electronic Library Online

 
vol.20 issue4Estimated quality of life and health related utility measurements in a population of Colombian patients with systemic lupus erythematosusAlendronate effects on cytokines and metalloproteases 2 and 9 profiles in an experimental arthritis murine model author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Reumatología

Print version ISSN 0121-8123

Abstract

LOPEZ, Yúrika Paola et al. Anti-C1q antibodies as markers of renal compromise in patients with systemic lupus erythematosus. Rev.Colomb.Reumatol. [online]. 2013, vol.20, n.4, pp.195-201. ISSN 0121-8123.

Summary Renal involvement in systemic lupus erythematosus (SLE) is one of the major determinants Anti-C1q antibodies of the course and prognosis of these patients. There is evidence of the association of Anti-DNA antibodies anti-C1q antibodies and the development of lupus nephritis. The aim of this study was to determine the prevalence of anti-C1q antibodies and its association with lupus nephritis in Colombian patients with SLE. Methods: 80 SLE patients as defined by the American College of Rheumatology criteria. Quantification of anti-C1q antibodies in patients' sera was performed by ELISA and concentrations greater than 15U/ml were considered positive. Results: Patients were predominantly women (87%) and 43.7% of them had proteinuria > 0.5 g / 24 hours which was more common in younger patients and early in the course of the disease. Forty-four (55%) of patients had positive anti-C1q, in whom, proteinuria was more frequent (OR = 4.3 95% CI 1.7 - 11, p = 0.003). A weak inverse correlation between anti-C1q titers, C3 consumption (r = -0.54, p <0.001) and creatinine clearance was found (r = -0.33, p = 0.035); similarly, we also found a weak direct correlation with proteinuria (r = 0.35, p = 0.024) and disease activity ascertained with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (r = 0.48, p <0.0001). Conclusions: Anti-C1q antibodies might be valuable for the evaluation of active lupus nephritis, and might be valuable for the evaluation of active lupus nephritis, and could be included as a diagnostic marker of lupus nephritis and maybe as a marker for disease activity, as suggested by the European League Against Rheumatism (EULAR).

Keywords : Anti-C1q antibodies; Anti-DNA antibodies; Lupus nephritis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )